| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Departments of Neuro-Oncology [Y-H. Z., F. T., W. K. A. Y.] and Biostatistics [K. R. H.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Experimental Design: cDNAs were generated by reverse transcriptase using mRNAs from gliomas and adjacent normal tissues from 86 patients. The tissues used for analysis were 45 AAs, 42 GBMs, and 7 samples of adjacent normal tissue. The levels of PAX6, PTEN, vascular endothelial growth factor (VEGF), and epidermal growth factor receptor (EGFR) gene expression were quantified using real-time quantitative reverse transcription-PCR and normalized to ß-actin. All statistical tests used were two-sided.
Results: PAX6 expression was significantly reduced in GBM compared with AA (P < 0.0001). The relative levels of PTEN, EGFR, and VEGF expression also differed significantly among glioma grades. Multivariate Cox analysis of glioma samples, adjusting for patient age, histology, recurrent status, and levels of PTEN, EGFR, VEGF, and PAX6 (7 variables) showed a correlation between a low level of PAX6 expression in malignant astrocytic gliomas and unfavorable patient outcomes (hazard ratio, 0.34; 95% confidence interval, 0.18–0.63). Recursive partitioning analysis showed a favorable outcome for patients with high expression values of PTEN and PAX6 compared with low expression values of one or both genes (P < 0.0001).
Conclusion: The expression levels of PAX6, PTEN, and VEGF but not EGFR were independent prognostic markers, and the model including 7 variables was able to account for 55% of the variation in survival times for malignant astrocytic glioma patients.
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Malignant astrocytic gliomas either arise de novo (primary) or from the progression of lower-grade astrocytic gliomas (secondary). The most frequent genetic anomalies found in primary GBM are a gain of chromosome 7 and amplification of the EGFR gene, LOH of chromosome 10, and mutation or deletion of the PTEN and p16 tumor suppressor genes (5, 6, 7, 8, 9) . Frequent occurrences of mutations of the p53 tumor suppressor gene and alteration of genes involved at the G1-S checkpoint have been observed in secondary GBM and AA patients (10 , 11) .
Of particular importance is that in addition to mutagenesis, the expression of specific genes correlates with gliomagenesis and with patient outcomes. The expression of PTEN, for one, is inversely correlated with the progression of GBM and a poor patient outcome (12) . VEGF is well known as an important angiogenic factor and as a prognosticator of glioma progression (13) , as demonstrated by reports of its overexpression in HT glioma cell lines and high-grade gliomas (14 , 15) . EFGR gene amplification has also been reported in many cases of GBM and has been implicated as playing an important role in tumor progression (16 , 17) . Less well known is the role of the PAX6 gene. Located on 11p13, this gene encodes a transcription factor composed of two DNA-binding domains: a paired domain and a paired-like homeodomain (18) . PAX6 is critical for the development of the eye, brain, and pancreas, and, in normal adults, it is continuously expressed in these organs (19, 20, 21, 22) . We observed differential PAX6 levels (protein and RNA) in different grades of glioma, with greater expression in HT than in NT glioma cell lines (23) .
As reported here, our use of real-time quantitative RT-PCR on cDNA samples confirmed the differential expression of the PAX6 gene in glioma cell lines. Furthermore, we quantified PAX6, PTEN, VEGF, and EGFR gene expression in cDNA samples from 87 malignant gliomas (45 AAs and 42 GBMs). This article reports our assessment of the prognostic values of these four genes, adjusted for the clinical variables of age, histology, and recurrent status, and compares the use of a three-variable model with the prognostic acuity of a seven-variable model.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Glioma cDNA Samples.
cDNA samples of gliomas and some adjacent normal tissues were created and used previously by Sano et al. (12)
. All of the specimens were obtained from patients who underwent therapeutic procedures at UTMDACC. Sections of samples were histologically evaluated by board-certified neuropathologists and classified according to a modified Ringertz grading system (12)
. Specimens were snap-frozen in liquid nitrogen and stored at -80°C. The purity of the tumor samples was estimated by using H&E staining to ensure that each sample contained >70% neoplastic cells. mRNAs were isolated from 10 frozen sections of each tumor specimen.
LC Quantitative Real-Time PCR.
Gene expression was quantified using a LC Instrument and LC DNA Master SYBR Green I enzyme mix (Roche, Indianapolis, IN) with primers, and the cDNA standard made for the PAX6, PTEN, EGFR, VEGF, ß-actin, GAPDH, enolase-
, and RPS9 genes. Because there are many alternative splicing forms of the PAX6, EGFR, and VEGF genes, the PCR primer sets were designed to amplify all of the transcripts from each gene according to information in GenBank. The primer sequences are: PAX6, 5'-GAATCAGAGAAGACAGGCCA-3' and 5'-GTGTAGGTATCATAACTCCG-3', ß-actin, 5'-TCCTTCCTGGGCATGGAGT-3' and 5'-AAAGCCATGCCAATCTCATC-3'; GAPDH, 5'-ATGGGGAAGGTGAAGGTCGG-3' and 5'-GACGGTGCCATGGAATTTGC-3'; RPS9, 5'-GAAGCTGATCGGCGAGTATG-3' and 5'-AGAGAAGTCAAGTGCTTCTG-3'; enolase-: 5'-AGTGGCTAGAAGTTCACC-3' and 5'-TGGCAGGATGACTTCAGA-3'; PTEN, 5'-CGAACTGGTGTAATGATATGT-3' and 5'-CATGAACTTGTCTTCCCGT-3'; VEGF, 5'-ATCACGAAGTGGTGAAGTTC-3' and 5'-TGCTGTAGGAAGCTCATCTC-3'; and EGFR, 5'-GACAGCTATGAGATGGAGGAA-3' and 5'-GAGTCACCCCTAAATGCCA-3'. The real-time quantitative RT-PCR standard for each gene is a serial dilution by 1 order of magnitude of a PCR-amplified cDNA fragment of each gene.
The LC real-time PCR reaction for each gene was conducted in a 10-µl volume, in LC glass capillaries, containing 0.5 µM primers, with the MgCl2 concentration optimized for each pair of primers between 2 and 3.5 mM. A typical protocol involved an initial denaturation at 95°C for 1 min, followed by 45 cycles of 95°C for 0 s, 60°C (VEGF)/62°C (GAPDH, ß-actin, enolase-, RPS9, PAX6, and PTEN)/64°C (EGFR) for 5 s, and 72°C elongation for 9 s (EGFR)/10–15 s (VEGF, PTEN, PAX6, GAPDH, ß-actin, enolase-, and RPS9). Fluorescence was measured at 72°C for EGFR, 80°C for PTEN, 82°C for VEGF, and 83°C for PAX6, GAPDH, ß-actin, enolase-, and RPS9. A standard melting-curve cycle was used to check the quality of amplification, such as no primer dimer being formed during PCR. To ensure accuracy, each reaction was repeated two to five times. The correlation coefficients r = 1.00 and the SE of the regression <0.1 were normally achieved for crossing points and log concentrations of seven 10-fold dilutions (101–107 molecules) of the standard DNA. The number of target copies in the specimens is normally within a range of 102–106, ensuring accurate determination. The real-time RT-PCR reaction for each sample was performed two to six times.
Prognostic Data.
Prognostic data for each patient were collected from The Brain Tumor Center database at UTMDACC. Survival times were calculated from the date of initial surgery. All of the patients were treated with similar regimens, which included surgery followed by radiation therapy and/or chemotherapy. Ratios of PAX6, PTEN, EGFR, and VEGF expression were correlated with survival, and were analyzed using a Cox proportional hazards regression analysis. The Kaplan-Meier method was used to estimate, and the Cox-Mantel log-rank test was used to compare survival distributions. All of the statistical analyses were performed using S-PLUS 2000 computer software (MathSoft Inc., Seattle, WA).
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
To select a good internal control for quantifying PAX6 expression, we measured the expression of GAPDH, ß-actin, enolase-, and RPS9, genes that have been used frequently as internal controls in semiquantitative or quantitative RT-PCR experiments. We determined which control gene(s) were expressed most stably in these glioma cell lines and found that the expression of GAPDH and enolase- correlated best (r = 0.85). PAX6:GAPDH and PAX6:enolase- ratios were then calculated and used to represent the relative levels of PAX6 expression. We included a normal astrocytic cell line, NHA, for comparing the relative expression of the PAX6 gene in different glioma cell lines. As shown in Fig. 1A
, a marked difference existed between the normalized ratios of PAX6:GAPDH and PAX6:enolase- in the NHA cell line compared with the ratios found in the glioma cell lines, suggesting that GAPDH and enolase- gene expression levels are strikingly different between normal astrocytic and glioma cell lines. Because reintroducing chromosome 10 into the U251 GBM cell line completely suppressed tumor formation in nude mice (24)
, we included three U251 chromosome 10 hybrid clones (N10) in this analysis. As shown in Fig. 1A
, PAX6 was expressed at a relatively low level in HT cells and at a relatively high level in NT glioma cell lines, and these differences were significant (P < 0.001; Fig. 1B
).
|
Because there is no reliable way to know the precise amount of cDNA used, an internal control gene was used to normalize the results. Because we would not expect levels of housekeeping genes to vary between two groups of tumors with different histologies if they were expressed stably, we used each to normalize the others to determine through t test analysis which one yielded the least significant differences between grade III and IV histologies. RPS9 gene expression differed significantly among the AA and GBM groups (P < 0.05), so its expression was eliminated as a useful internal control. Although the levels of expression of the other three housekeeping genes did not differ significantly between the two groups (P > 0.4), the ß-actin gene had the largest P (data not shown) and was selected for calculating and statistically analyzing gene ratios.
As shown in Table 1
, the median relative expression of PAX6 and PTEN genes in AA is greater than that in GBM by >3-fold and 2-fold, respectively. The median relative expression levels of the EGFR and VEGF genes in GBM is greater than in AA by >2-fold and 4-fold, respectively. No marked change in gene expression was found in the AA and normal samples for the PAX6, PTEN, and VEGF genes, except for a 1.7-fold increase in EGFR gene expression in AA compared with normal tissue samples.
|
shows that all of the genes of interest were expressed heterogeneously in various tissues. Overall, however, PAX6 gene expression in GBM was significantly reduced compared with that in AA (P < 0.0001; Fig. 2A
). The Wilcoxon Ps were each <0.0001 for PAX6 normalized by enolase- and GAPDH among GBM and AA specimens (data not shown).
|
. For AA patient #7, no marked differences were apparent between values from tumor and surrounding normal tissue. For patient #8, who was initially diagnosed as having AA with a later recurrence as GBM, PAX6 gene expression was 
31-fold higher in the AA than in the GBM specimen. A Wilcoxon rank-sum test showed that the difference in PAX6 expression was significant (P = 0.0014) when GBM PAX6 gene expression (n = 42) was compared with its expression in normal specimens (n = 7), but was not significant (P = 0.67) when AA samples (n = 45) were compared with normal samples. The combined results suggest that decreased PAX6 expression correlates with GBM development.
|
). Our results are also in accord with reports of VEGF gene overexpression in GBM after immunohistologic staining (15)
. We found a significantly higher level of VEGF gene expression in GBM than in AA (P = 0.0002; Fig. 2C
). Although the difference is not as striking as for the other three genes studied, the expression of EGFR gene in GBMs is significantly higher than in AAs (P = 0.046; Fig. 2D
). Additional analysis of GBM versus AA comparing the expression of all four of the genes using a logistic regression analysis suggested that expression of the PAX6 and VEGF genes is diversely distributed among GBM and AA histologies (P = 0.0004 and P = 0.0005, respectively). GBM tends to have high levels of VEGF expression and low levels of PAX6 expression, whereas the opposite is true in AA, with a tendency toward high PAX6 and low VEGF expression.
Analysis of Survival.
Of the 86 glioma patients whose tumor specimens were used (1 AA and 1 GBM are from 1 patient), 70 had died by the time of analysis. The two main clinical variables that correlated with survival were tumor grade and tumor recurrence status. For the 45 AA patients, median survival was 117 weeks, whereas for the 42 GBM patients, median survival was only 44 weeks. In 63 newly diagnosed patients, median survival was 80 weeks, whereas the median survival was 32 weeks for 23 patients after tumor recurrence. In a Cox proportional hazards regression analysis model taking into account the variables of age, histology (GBM versus AA), and recurrence status, the adjusted hazard ratio for GBM versus AA was 3.0, and the adjusted hazard ratio for recurrence was 2.2. However, this model accounted for only 30% of the variation in survival times for GBM and AA.
To improve the survival model, we included the relative values of PAX6, PTEN, VEGF, and EGFR gene expression through a series of Cox proportional hazards regression analyses. The approach we used was to select cutpoints for the level of expression of each gene, and by dichotomizing, groups were formed above and below the cutpoint. The best cutpoint for each gene was selected using recursive partitioning analysis of residuals adjusted for age, histology, and disease recurrence status. As shown in Fig. 3
, a lower value of PAX6 expression is an unfavorable prognostic factor for malignant glioma patients. The univariate hazard ratio for patients with higher values compared with those with lower values is 0.39 (95% CI, 0.24–0.64) and the adjusted hazard ratio using the seven covariates is 0.34 (95% CI, 0.18–0.63).
|
shows that the Ps from univariate analyses of all four of the genes were significant (P < 0.01) except for EGFR. The Ps for each gene, which were derived from an analysis adjusted for age, histology, and recurrence, yielded greatly increased values over a simple univariate approach. This finding is consistent with the observation that gene expression values and survival correlate with tumor grade. Although a confounding effect exists between gene expression and clinical variables, the Ps nevertheless showed significance for PAX6, PTEN, and VEGF after adjusting for age, histology, and tumor recurrence. The Ps for EGFR were not significant. Using log-transformed relative gene expression values in a series of Cox proportional hazards regression analyses, we obtained results that were similar to those obtained from using cutpoints, bolstering the validity of the findings.
|
. Thus, the relative expression values of all three of the genes are clearly independent prognostic markers of tumor grade. Consistent with this conclusion and as shown in Table 4
, the proportion of variation in survival explained by the model with three clinical variables (30%) increased when the relative value of the expression for each gene was included, except for EGFR (36%–39%). In contrast, when seven variables were included in the model, 55% of the variation in survival times was accounted for.
|
is a Kaplan-Meier survival curve based on the values of PAX6 and PTEN gene expression. The hazard ratio for patients with higher values for both PAX6 and PTEN gene expression compared with those with lower values for both is 0.1 (95% CI, 0.005–0.3). The hazard ratio for patients with mixed values compared with those with lower values for both is 0.5 (95% CI, 0.3–0.8). When all three groups of patients were segregated by the values of expression of the PAX6 and PTEN genes, significant differences in survival were found (P < 0.0001). These results were unchanged after adjusting for age, histology, and tumor recurrence status.
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Although EGFR gene amplification and overexpression were seen in some gliomas, its expression has no prognostic value according to our analysis. In the case of EGFR gene amplification, there are frequent and various mutations of different regions of the gene that could lead to the increased or decreased oncogenic activity of EGFR (25) . In some cases, however, the total number of EGFR transcripts cannot account for the functional level of EGFR. Quantifying the levels of alternatively spliced EGFR transcripts that have enhanced oncogenic activity, such as EGFRvIII, may improve its prognostic value.
Turning our attention to PAX6 gene expression, we wished to determine if its down-regulation in GBMs was affected by the LOH of chromosome 10, which occurred predominantly in the specimens studied here (26)
, or if it was merely a side effect of the LOH of chromosome 10. After we screened nine chromosome 10 U251-hybrid clones that did not produce tumors in nude mice (24)
, we found markedly increased RNA and PAX6 protein compared with the parental U251 cell line and with U251 chromosome 2 hybrid cells (Fig. 1A)
.4
Interestingly, some of the chromosome 10 hybrid clones retained only a partially exogenous chromosome 10, the region marked as 10pter-q11 (27)
. This finding suggests that gene(s) on 10pter-q11 up-regulate PAX6 expression, whereas the tumor suppressor genes in 10q do not, including the PTEN gene located on 10q23.3. This result is in accord with the expression level of PAX6 not being up-regulated in U251 cells overexpressing PTEN.4
Although PAX6 and PTEN expression in the glioma specimens from this study are minimally correlated (r = 0.31), this correlation likely occurs because of LOH of the entire, or of a large portion of, chromosome 10. Significantly, however, the relative values of PAX6 and PTEN gene expression are two independent and powerful prognostic markers of outcome for patients with astrocytic malignant gliomas.
Overall, our real-time quantitative RT-PCR approach of quantifying the relative values of PAX6 gene expression in gliomas, together with PTEN and VEGF gene expression from the small amount of cDNA available, has clinical importance for its ability to prognosticate survival in individual cases and within tumor grades. We observed overlaps between two groups of AAs and GBMs (Fig. 2)
, which could be because of the heterogeneity and genomic instability inherent in malignant gliomas. Because clinical outcomes are highly variable for patients with these gliomas, we anticipate a better classification of these patients by identifying certain prognostic gene expression variables in the tumors. Although our model that included seven variables was greatly improved from the earlier model that included only three clinical variables, increasing the prognostic ability of the model from 30% to 55%, we anticipate additionally improving the power of the survival model for glioma patients by including additional independent prognostic variables in future studies.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 Supported by the National Research Service Award Grant 5 F32 EY06949-02 and the Gilliland Foundation for Brain Tumor Research. 
2 To whom requests for reprints should be addressed, at Department of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: (713) 745-1285; Fax: (713) 745-4999; E-mail: wyung{at}mdanderson.org
3 The abbreviations used are: AA, anaplastic astrocytoma; GBM, glioblastoma multiforme; RT-PCR, reverse transcription-PCR; VEGF, vascular endothelial growth factor; EGFR, epidermal growth factor receptor; LOH, loss of heterozygosity; UTMDACC, University of Texas M. D. Anderson Cancer Center; LC, LightCycler; HT, highly tumorigenic; NT, nontumorigenic; CI, confidence interval.
Received 9/30/02; revised 2/24/03; accepted 2/24/03.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  K. Sakurai and N. Osumi The Neurogenesis-Controlling Factor, Pax6, Inhibits Proliferation and Promotes Maturation in Murine Astrocytes J. Neurosci., April 30, 2008; 28(18): 4604 - 4612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Norden, G. S. Young, K. Setayesh, A. Muzikansky, R. Klufas, G. L. Ross, A. S. Ciampa, L. G. Ebbeling, B. Levy, J. Drappatz, et al. Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence Neurology, March 4, 2008; 70(10): 779 - 787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Dickinson, B. K. Sturges, R. J. Higgins, B. N. Roberts, C. M. Leutenegger, A. W. Bollen, and R. A. LeCouteur Vascular Endothelial Growth Factor mRNA Expression and Peritumoral Edema in Canine Primary Central Nervous System Tumors Vet. Pathol., March 1, 2008; 45(2): 131 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gilabert-Estelles, L.A. Ramon, F. Espana, J. Gilabert, V. Vila, E. Reganon, R. Castello, M. Chirivella, and A. Estelles Expression of angiogenic factors in endometriosis: relationship to fibrinolytic and metalloproteinase systems Hum. Reprod., August 1, 2007; 22(8): 2120 - 2127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R.J. Carlson, W. B. Pope, S. Horvath, J. G. Braunstein, P. Nghiemphu, C.-L. Tso, I. Mellinghoff, A. Lai, L. M. Liau, P. S. Mischel, et al. Relationship between Survival and Edema in Malignant Gliomas: Role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2 Clin. Cancer Res., May 1, 2007; 13(9): 2592 - 2598. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Heister, A. Hayar, A. Charlesworth, C. Yates, Y.-H. Zhou, and E. Garcia-Rill Evidence for Electrical Coupling in the SubCoeruleus (SubC) Nucleus J Neurophysiol, April 1, 2007; 97(4): 3142 - 3147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Akhter, B. W. Johnson, C. Crane, M. Iruthayanathan, Y.-H. Zhou, A. Kudo, and G. V. Childs Anterior Pituitary Leptin Expression Changes in Different Reproductive States: In Vitro Stimulation by Gonadotropin-releasing Hormone J. Histochem. Cytochem., February 1, 2007; 55(2): 151 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Mayes, Y. Hu, Y. Teng, E. Siegel, X. Wu, K. Panda, F. Tan, W.K. A. Yung, and Y.-H. Zhou PAX6 Suppresses the Invasiveness of Glioblastoma Cells and the Expression of the Matrix Metalloproteinase-2 Gene. Cancer Res., October 15, 2006; 66(20): 9809 - 9817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Wei, L. Clarke, D. K. Scheidenhelm, B. Qian, A. Tong, N. Sabha, Z. Karim, N. A. Bock, R. Reti, R. Swoboda, et al. High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. Cancer Res., August 1, 2006; 66(15): 7429 - 7437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Liu, B. Dai, S.-H. Kang, K. Ban, F.-J. Huang, F. F. Lang, K. D. Aldape, T.-x. Xie, C. E. Pelloski, K. Xie, et al. FoxM1B Is Overexpressed in Human Glioblastomas and Critically Regulates the Tumorigenicity of Glioma Cells. Cancer Res., April 1, 2006; 66(7): 3593 - 3602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Iruthayanathan, Y.-H. Zhou, and G. V. Childs Dehydroepiandrosterone Restoration of Growth Hormone Gene Expression in Aging Female Rats, in Vivo and in Vitro: Evidence for Actions via Estrogen Receptors Endocrinology, December 1, 2005; 146(12): 5176 - 5187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-H. Zhou, K. R. Hess, L. Liu, Mark. E. Linskey, and W.K. A. Yung Modeling prognosis for patients with malignant astrocytic gliomas: Quantifying the expression of multiple genetic markers and clinical variables Neuro-oncol, October 1, 2005; 7(4): 485 - 494. [Abstract] [PDF]
|
|
|
|
|
|
S. J. Kim, H. Uehara, S. Yazici, R. R. Langley, J. He, R. Tsan, D. Fan, J. J. Killion, and I. J. Fidler Simultaneous Blockade of Platelet-Derived Growth Factor-Receptor and Epidermal Growth Factor-Receptor Signaling and Systemic Administration of Paclitaxel as Therapy for Human Prostate Cancer Metastasis in Bone of Nude Mice Cancer Res., June 15, 2004; 64(12): 4201 - 4208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Bepler, S. Sharma, A. Cantor, A. Gautam, E. Haura, G. Simon, A. Sharma, E. Sommers, and L. Robinson RRM1 and PTEN As Prognostic Parameters for Overall and Disease-Free Survival in Patients With Non-Small-Cell Lung Cancer J. Clin. Oncol., May 15, 2004; 22(10): 1878 - 1885. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
) or GAPDH (
), and the value of 1 was assigned for U251. N10.5.6, N10.6, and N10.8 are U251-chromosomal 10 hybrid clones. NHA is a normal astrocytic cell line. The tumorigenicity of each cell line in nu/nu mice (LT, low tumorigenic) is from Ke et al. 
